Clinical trial · Interventional
Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Through a retrospective study of patients who underwent comprehensive treatment for hepatocellular carcinoma at the Second Affiliated Hospital of Zhejiang University, we explored the risk factors related to the sensitivity of comprehensive treatment. We used the PD-L1 expression level of patients before comprehensive treatment，characteristic morphology of tertiary lymphoid structures, as well as other parameters, are used to construct a liver cancer comprehensive treatment efficacy evaluation model. Using this liver cancer comprehensive treatment efficacy evaluation model, we conducted a randomized controlled trial on whether to receive comprehensive treatment for liver cancer patients to verify the accuracy and practical value of the model.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Immunotherapy | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immunotherapy combined with targeted therapy | Procedure | — | UNRESOLVED |
| Standard treatment plan | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Comprehensive treatment group
- description
- Immunotherapy combined with targeted therapy
- interventionNames
- Procedure: Immunotherapy combined with targeted therapy
- type
- ACTIVE_COMPARATOR
- label
- non-comprehensive treatment group
- description
- Standard treatment plan
- interventionNames
- Other: Standard treatment plan
Primary outcomes (2)
- measure
- Evaluation of the efficacy of patient treatment
- timeFrame
- Long-term follow-up of patients after treatment through the study completion, an average of 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with advanced hepatocellular carcinoma Exclusion Criteria: * Have comorbidities of severe diabetes, heart failure, liver and/or kidney failure * Have a history of schizophrenia * Have a history of other malignant tumors or metastatic liver tumors discovered after surgery * Received anti-tumor drugs for other diseases * Special groups such as pregnant and lactating women.
References
Publications (0)
Data not yet available